You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Obstructive Sleep Apnea and Inflammation: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Respiratory System
Contributor: David Gozal

Obstructive sleep apnea syndrome (OSAS) is a markedly prevalent condition across the lifespan, particularly in overweight and obese individuals, which has been associated with an independent risk for neurocognitive, behavioral, and mood problems as well as cardiovascular and metabolic morbidities, ultimately fostering increases in overall mortality rates.

  • sleep apnea
  • inflammation
  • cytokines
  • interleukin 6
  • morbidity
  • tumor necrosis factor
  • end-organ injury

1. Obstructive Sleep Apnea Syndrome (OSAS) and Morbidity

Obstructive sleep apnea syndrome (OSAS) is characterized by recurring events of partial or complete upper airway collapse during sleep, resulting in altered alveolar ventilation, intermittent hypoxemia along with increased respiratory efforts and intra-thoracic negative pressure swings that frequently lead to arousal and therefore perturb sleep continuity and result in fragmented sleep architecture. Obesity is a major risk factor of OSAS [1][2][3][4][5][6][7], and both of these conditions impose adverse neurocognitive, mood, behavioral, cardiovascular, and metabolic consequences in both children and adults. In addition, as the awareness and consequently the frequency of diagnosing OSAS have increased, a large list of additional OSAS-associated morbidities has been reported, including chronic kidney disease, erectile dysfunction, ocular conditions, Alzheimer disease, nocturia, and even cancer in adults, while in children enuresis and bruxism are frequent adverse consequences [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. Efforts are ongoing to develop new and more effective therapies for OSAS based on underlying mechanisms promoting upper airway collapsibility during sleep [32][33]. However, the current first line treatment for OSAS in children is surgical adenotonsillectomy (T&A) and in adults consists of the administration of nasal continuous positive airway pressure (CPAP) therapy, both of which can result in transformative outcomes [34].
Although OSAS is associated with a 2–3-fold increased risk of developing a large spectrum of end-organ morbidities, not all patients with OSAS manifest evidence of any given end-organ dysfunction. The variability of the clinical phenotype has prompted intense investigation, especially focused around the role of systemic inflammation in OSAS-associated morbidities, particularly those affecting neurocognitive, cardiovascular, or metabolic functions [35][36][37][38][39][40][41][42]. However, exploration of systemic inflammatory pathways as candidate biomarkers failed to identify distinctive panels of circulating inflammatory markers that accurately differentiated between at-risk OSAS pediatric patients from those who appear to be less susceptible [20][43][44][45][46][47][48][49][50][51][52]. These are problematic findings since many of the OSAS morbidities are usually silent, progressive, and potentially reversible during earlier stages but can slowly progress to become either irreversible or only partially reversible over time [53][54]. Moreover, because the interactions between OSAS and obesity are multifaceted, it is difficult to identify exclusive OSAS biomarkers, since obesity can usually alter the expression and circulating levels of such biomarkers, and vice versa [55][56][57][58][59][60][61][62]. In addition, treatment of OSAS has been associated with worsening obesity [63], which can potentially dampen the response of inflammatory biomarkers to treatment. 

2. Tumor Necrosis Factor-α

Tumor necrosis factor-α (TNF-α) is a classic pro-inflammatory cytokine that has been implicated in the regulation of sleep [64][65][66][67]. Systemic administration of TNF-α promotes the probability and depth of physiological sleep states, particularly enhancing the time spent in non-rapid eye movement (NREM) sleep phase. In addition, TNF-α levels exhibit circadian patterns, are enhanced following sleep deprivation, and the targeted disruption of TNF-α receptors or their inhibition in the CNS will result in the suppression of spontaneous NREM sleep [62]. Of note, TNF-α will traditionally lead to the activation of NF-κB pathways that in turn activate nitric oxide synthase, cyclooxygenase 2, and adenosine A1 receptors, all of which are implicated in sleep regulation [64][65][66][67]. Sleep fragmentation paradigms mimicking the sleep disruption that characterizes OSAS induces substantial up-regulation of TNF-α expression in the CNS and other tissues in mice, along with increased sleep propensity along with cognitive and mood disturbances, similar to those occurring in OSAS, even in the absence of restricted sleep duration [68][69]. Moreover, treatment with a TNF-α neutralizing antibody in wild-type mice subjected to fragmented sleep, or when the same sleep perturbation is applied to double TNF-α receptor null mice, results in marked attenuation of the increased sleep propensity as well as in attenuation of the cognitive and behavioral disturbances induced by sleep disruption [70][71]. In addition to the intrinsic causal link between sleep perturbations and TNF-α demonstrated in both murine and human experiments, similar studies in mice focused on the chronic intermittent hypoxia that characterizes OSAS further demonstrated the recruitment of TLR-4-NF-κB pathways along with increased cellular and extracellular levels of TNF-α, thereby lending further credence to the pathophysiological role of this cytokine in the context of OSAS [70][71][72][73][74][75][76][77][78][79][80][81][82][83][84].
In addition to OSAS or its intrinsic components fostering a pro-inflammatory state and manifesting as increased circulating levels of TNF-α, it is also possible that the reciprocal relationships might favor the emergence of upper airway dysfunction or of other mechanisms that facilitate the onset of OSAS. For example, intermittent hypoxia can generate inflammatory processes in the carotid body, which then translate into altered immunoregulation as well as perturbations in control of breathing that may facilitate the propensity for respiratory instability during sleep [85][86][87][88][89][90][91]. Furthermore, although specific studies are lacking in relation to upper airway musculature, increases in TNF-α in the context of other conditions (e.g., obesity) may promote muscle dysfunction and therefore enhance the likelihood of upper airway dysfunction [92][93][94].

3. Interleukin 6

Interleukin 6 (IL-6) belongs to the so-called IL-6 family of cytokines. All of its members, which include cardiotrophin-1, oncostatin M, leukemia inhibitory factor, cardiotrophin-like cytokine, ciliary neurotrophic factor, and the interleukins 11, 27, 30, and 31, bind to the glycoprotein 130 (gp130) as a β-receptor to activate intracellular signaling cascades. These cascades generally consist of homo- or heterodimers of gp130 in combination with other cytokine receptors [95]. Plasma levels of the inflammatory biomarker hs-CRP, whose expression is IL-6 dependent in liver, predict the risk of vascular disease in addition to other disease conditions such as diabetes and cognitive function deterioration. In the context of OSAS, hs-CRP levels tend to be elevated in afflicted children, independent of the degree of obesity [38]. Adipose tissue inflammation is induced by intermittent hypoxia and by chronic sleep fragmentation, can result in elevated IL-6 release [96][97][98][99][100][101][102], and may cross-talk with endothelial cells via adipocyte-derived mediators such as IL-6 to promote NF-κB-dependent endothelial dysfunction [103].
Furthermore, IL-6 plasma levels correlate with endothelial dysfunction, arterial stiffness, and the magnitude of subclinical atherosclerosis and are also predictive of incident type 2 diabetes and obesity [104][105]. The marked overlap between the repertoire of conditions in which IL-6 is either a risk biomarker or an actual effector of morbidity and the OSAS morbid consequences suggest that IL-6 may serve as a reliable reporter of either the presence of OSAS or of the risk of OSAS-associated morbidities. This assumption is further buttressed by the fact that intermittent hypoxia, one of the hallmark characteristics of OSAS, induces polarization of macrophages along with increased production of IL-6 [106]. Biopsies of adipose tissue and blood samples in obese patients with and without OSAS, revealed substantial increases in tissue expression and circulating levels of a variety of pro-inflammatory cytokines, including IL-6, and such changes were markedly attenuated by six months of CPAP therapy [107]. Interestingly, adult patients with OSAS and objective EDS documented by reduced sleep latencies exhibited significantly elevated daytime and nighttime IL-6 plasma levels, that were absent when no EDS was present [108]. Pooling of eight published reports in adults with OSAS revealed that plasma levels of IL-6 ranged from 1.2 to 131.66 pg/mL before CPAP treatment and significantly decreased to between 0.45 to 66.04 pg/mL after CPAP treatment (p < 0.05), but they also indicated that there was significant inter-individual heterogeneity [109]. Similar heterogeneity was detected in IL-6 levels in children with OSAS [110][111][112][113][114] and may be related to genetic variance for both IL-6 and CRP genes [114].

This entry is adapted from the peer-reviewed paper 10.3390/ijms20030459

References

  1. Jordan, A.S.; McSharry, D.G.; Malhotra, A. Adult obstructive sleep apnoea. Lancet 2014, 383, 736–747.
  2. Owens, R.L.; Malhotra, A.; Eckert, D.J.; White, D.P.; Jordan, A.S. The influence of end-expiratory lung volume on measurements of pharyngeal collapsibility. J. Appl. Physiol. 2010, 108, 445–451.
  3. Tauman, R.; Gozal, D. Obesity and obstructive sleep apnea in children. Paediatr. Respir. Rev. 2006, 7, 247–259.
  4. Dayyat, E.; Kheirandish-Gozal, L.; Sans Capdevila, O.; Maarafeya, M.M.A.; Gozal, D. Obstructive sleep apnea in children: Relative contributions of body mass index and adenotonsillar hypertrophy. Chest 2009, 136, 137–144.
  5. Brenner, R.; Kivity, S.; Peker, M.; Reinhorn, D.; Keinan-Boker, L.; Silverman, B.; Liphsitz, I.; Kolitz, T.; Levy, C.; Shlomi, D.; et al. Increased Risk for Cancer in Young Patients with Severe Obstructive Sleep Apnea. Respiration 2019, 97, 15–23.
  6. Sillah, A.; Watson, N.F.; Schwartz, S.M.; Gozal, D.; Phipps, A.I. Sleep apnea and subsequent cancer incidence. Cancer Causes Control 2018, 29, 987–994.
  7. Martinez-Garcia, M.A.; Campos-Rodriguez, F.; Nagore, E.; Martorell, A.; Rodriguez-Peralto, J.L.; Riveiro-Falkenbach, E.; Hernandez, L.; Bañuls, J.; Arias, E.; Ortiz, P.; et al. Sleep-Disordered Breathing Is Independently Associated With Increased Aggressiveness of Cutaneous Melanoma: A Multicenter Observational Study in 443 Patients. Chest 2018, 154, 1348–1358.
  8. Malhotra, R.K. Neurodegenerative disorders and sleep. Sleep Med. Clin. 2018, 13, 63–70.
  9. Haba-Rubio, J.; Marti-Soler, H.; Tobback, N.; Andries, D.; Marques-Vidal, P.; Waeber, G.; Vollenweider, P.; von Gunten, A.; Preisig, M.; Castelao, E.; et al. Sleep characteristics and cognitive impairment in the general population: The HypnoLaus study. Neurology 2017, 88, 463–469.
  10. Heinzer, R.; Vat, S.; Marques-Vidal, P.; Marti-Soler, H.; Andries, D.; Tobback, N.; Mooser, V.; Preisig, M.; Malhotra, A.; Waeber, G.; et al. Prevalence of sleep-disordered breathing in the general population: The HypnoLaus study. Lancet Respir. Med. 2015, 3, 310–318.
  11. Drager, L.F.; McEvoy, R.D.; Barbe, F.; Lorenzi-Filho, G.; Redline, S.; INCOSACT Initiative (International Collaboration of Sleep Apnea Cardiovascular Trialists). Sleep apnea and cardiovascular disease: Lessons from recent trials and need for team science. Circulation 2017, 136, 1840–1850.
  12. Leng, Y.; McEvoy, C.T.; Allen, I.E.; Yaffe, K. Association of sleep-disordered breathing with cognitive function and risk of cognitive impairment: A systematic review and meta-analysis. JAMA Neurol. 2017, 74, 1237–1245.
  13. Abuzaid, A.S.; Al Ashry, H.S.; Elbadawi, A.; Ld, H.; Saad, M.; Elgendy, I.Y.; Elgendy, A.; Mahmoud, A.N.; Mentias, A.; Barakat, A.; et al. Meta-analysis of cardiovascular outcomes with continuous positive airway pressure therapy in patients with obstructive sleep apnea. Am. J. Cardiol. 2017, 120, 693–699.
  14. Reutrakul, S.; Mokhlesi, B. Obstructive sleep apnea and diabetes: A state of the art review. Chest 2017, 152, 1070–1086.
  15. Ferini-Strambi, L.; Lombardi, G.E.; Marelli, S.; Galbiati, A. Neurological deficits in obstructive sleep apnea. Curr. Treat Options Neurol. 2017, 19, 16.
  16. Ehsan, Z.; Ishman, S.L.; Kimball, T.R.; Zhang, N.; Zou, Y.; Amin, R.S. Longitudinal cardiovascular outcomes of sleep disordered breathing in children: A meta-analysis and systematic review. Sleep 2017, 40.
  17. Javaheri, S.; Barbe, F.; Campos-Rodriguez, F.; Dempsey, J.A.; Khayat, R.; Javaheri, S.; Malhotra, A.; Martinez-Garcia, M.A.; Mehra, R.; Pack, A.I.; et al. Sleep apnea: Types, mechanisms, and clinical cardiovascular consequences. J. Am. Coll. Cardiol. 2017, 69, 841–858.
  18. Patinkin, Z.W.; Feinn, R.; Santos, M. Metabolic consequences of obstructive sleep apnea in adolescents with obesity: A systematic literature review and meta-analysis. Child. Obes. 2017, 13, 102–110.
  19. Zinchuk, A.V.; Gentry, M.J.; Concato, J.; Yaggi, H.K. Phenotypes in obstructive sleep apnea: A definition, examples and evolution of approaches. Sleep Med. Rev. 2017, 35, 113–123.
  20. Kheirandish-Gozal, L.; Gozal, D. Pediatric OSA syndrome morbidity biomarkers: The hunt is finally on! Chest 2017, 151, 500–506.
  21. Huon, L.K.; Liu, S.Y.; Camacho, M.; Guilleminault, C. The association between ophthalmologic diseases and obstructive sleep apnea: A systematic review and meta-analysis. Sleep Breath. 2016, 20, 1145–1154.
  22. Gokdemir, Y.; Ersu, R. Sleep disordered breathing in childhood. Eur. Respir. Rev. 2016, 25, 48–53.
  23. Koren, D.; Dumin, M.; Gozal, D. Role of sleep quality in the metabolic syndrome. Diabetes Metab. Syndr. Obes. 2016, 9, 281–310.
  24. Tan, H.L.; Gozal, D.; Kheirandish-Gozal, L. Obstructive sleep apnea in children: A critical update. Nat. Sci. Sleep 2013, 5, 109–123.
  25. Gozal, D.; Kheirandish-Gozal, L. The multiple challenges of obstructive sleep apnea in children: Morbidity and treatment. Curr. Opin. Pediatr. 2008, 20, 654–658.
  26. Gozal, D. Obstructive sleep apnea in children: Implications for the developing central nervous system. Semin. Pediatr. Neurol. 2008, 15, 100–106.
  27. Marrone, O.; Bonsignore, M.R. Obstructive sleep apnea and chronic kidney disease: Open questions on a potential public health problem. J. Thorac. Dis. 2018, 10, 45–48.
  28. Hwu, D.W.; Lin, K.D.; Lin, K.C.; Lee, Y.J.; Chang, Y.H. The association of obstructive sleep apnea and renal outcomes-a systematic review and meta-analysis. BMC Nephrol. 2017, 18, 313.
  29. Finamore, P.; Scarlata, S.; Laudisio, A.; Galdi, F.; Pipita, M.E.; Chiarella, I.; Giua, R.; Cortese, L.; Rivera, C.; Antonelli Incalzi, R. Occurrence of nocturia is not mediated by nocturnal hypoxia length and severity in patients with sleep-disordered breathing. Sleep Med. 2018, 45, 69–73.
  30. Carra, M.C.; Bruni, O.; Huynh, N. Topical review: Sleep bruxism, headaches, and sleep-disordered breathing in children and adolescents. J. Orofac. Pain 2012, 26, 267–276.
  31. Campos-Juanatey, F.; Fernandez-Barriales, M.; Gonzalez, M.; Portillo-Martin, J.A. Effects of obstructive sleep apnea and its treatment over the erectile function: A systematic review. Asian J. Androl. 2017, 19, 303–310.
  32. Sands, S.A.; Edwards, B.A.; Terrill, P.I.; Butler, J.P.; Owens, R.L.; Taranto-Montemurro, L.; Azarbarzin, A.; Marques, M.; Hess, L.B.; Smales, E.T.; et al. Identifying obstructive sleep apnea patients responsive to supplemental oxygen therapy. Eur. Respir. J. 2018, 1800674.
  33. Sands, S.A.; Edwards, B.A.; Terrill, P.I.; Taranto-Montemurro, L.; Azarbarzin, A.; Marques, M.; Hess, L.B.; White, D.P.; Wellman, A. Phenotyping Pharyngeal Pathophysiology using Polysomnography in Patients with Obstructive Sleep Apnea. Am. J. Respir. Crit. Care Med. 2018, 197, 1187–1197.
  34. Kaditis, A.G.; Alonso Alvarez, M.L.; Boudewyns, A.; Alexopoulos, E.I.; Ersu, R.; Joosten, K.; Larramona, H.; Miano, S.; Narang, I.; Trang, H.; et al. Obstructive sleep disordered breathing in 2- to 18-year-old children: Diagnosis and management. Eur. Respir. J. 2016, 47, 69–94.
  35. Almendros, I.; Gozal, D. Intermittent hypoxia and cancer: Undesirable bed partners? Respir. Physiol. Neurobiol. 2018, 256, 79–86.
  36. Gozal, D.; Farré, R.; Nieto, F.J. Obstructive sleep apnea and cancer: Epidemiologic links and theoretical biological constructs. Sleep Med. Rev. 2016, 27, 43–55.
  37. Bhattacharjee, R.; Kim, J.; Kheirandish-Gozal, L.; Gozal, D. Obesity and obstructive sleep apnea syndrome in children: A tale of inflammatory cascades. Pediatr. Pulmonol. 2011, 46, 313–323.
  38. Gozal, D.; Kheirandish-Gozal, L.; Bhattacharjee, R.; Kim, J. C-reactive protein and obstructive sleep apnea syndrome in children. Front. Biosci. 2012, 4, 2410–2422.
  39. Gozal, D.; Hakim, F.; Kheirandish-Gozal, L. Chemoreceptors, baroreceptors, and autonomic deregulation in children with obstructive sleep apnea. Respir. Physiol. Neurobiol. 2013, 185, 177–185.
  40. Kheirandish-Gozal, L.; Gozal, D. Genotype-phenotype interactions in pediatric obstructive sleep apnea. Respir. Physiol. Neurobiol. 2013, 189, 338–343.
  41. Zhang, S.X.; Wang, Y.; Gozal, D. Pathological consequences of intermittent hypoxia in the central nervous system. Compr. Physiol. 2012, 2, 1767–1777.
  42. Almendros, I.; Wang, Y.; Gozal, D. The polymorphic and contradictory aspects of intermittent hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 307, L129–L140.
  43. Khalyfa, A.; Kheirandish-Gozal, L.; Khalyfa, A.A.; Philby, M.F.; Alonso-Álvarez, M.L.; Mohammadi, M.; Bhattacharjee, R.; Terán-Santos, J.; Huang, L.; Andrade, J.; et al. Circulating plasma extracellular microvesicle microRNA cargo and endothelial dysfunction in children with obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2016, 194, 1116–1126.
  44. Kheirandish-Gozal, L.; Philby, M.F.; Alonso-Álvarez, M.L.; Terán-Santos, J.; Gozal, D. Biomarkers of Alzheimer disease in children with obstructive sleep apnea: Effect of adenotonsillectomy. Sleep 2016, 39, 1225–1232.
  45. Alkhouri, N.; Kheirandish-Gozal, L.; Matloob, A.; Alonso-Álvarez, M.L.; Khalyfa, A.; Terán-Santos, J.; Okwu, V.; Lopez, R.; Gileles-Hillel, A.; Dweik, R.; et al. Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea. Sleep Med. 2015, 16, 1031–1035.
  46. Kheirandish-Gozal, L.; Gileles-Hillel, A.; Alonso-Álvarez, M.L.; Peris, E.; Bhattacharjee, R.; Terán-Santos, J.; Duran-Cantolla, J.; Gozal, D. Effects of adenotonsillectomy on plasma inflammatory biomarkers in obese children with obstructive sleep apnea: A community-based study. Int. J. Obes. (Lond.) 2015, 39, 1094–1100.
  47. Gozal, D.; Kheirandish-Gozal, L.; Carreras, A.; Khalyfa, A.; Peris, E. Obstructive sleep apnea and obesity are associated with reduced GPR 120 plasma levels in children. Sleep 2014, 37, 935–941.
  48. Kim, J.; Gozal, D.; Bhattacharjee, R.; Kheirandish-Gozal, L. TREM-1 and pentraxin-3 plasma levels and their association with obstructive sleep apnea, obesity, and endothelial function in children. Sleep 2013, 36, 923–931.
  49. Kim, J.; Bhattacharjee, R.; Khalyfa, A.; Kheirandish-Gozal, L.; Capdevila, O.S.; Wang, Y.; Gozal, D. DNA methylation in inflammatory genes among children with obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2012, 185, 330–338.
  50. Kim, J.; Lee, S.; Bhattacharjee, R.; Khalyfa, A.; Kheirandish-Gozal, L.; Gozal, D. Leukocyte telomere length and plasma catestatin and myeloid-related protein 8/14 concentrations in children with obstructive sleep apnea. Chest 2010, 138, 91–99.
  51. Khalyfa, A.; Kheirandish-Gozal, L.; Gozal, D. Circulating exosomes in obstructive sleep apnea as phenotypic biomarkers and mechanistic messengers of end-organ morbidity. Respir. Physiol. Neurobiol. 2018, 256, 143–156.
  52. De Luca Canto, G.; Pachêco-Pereira, C.; Aydinoz, S.; Major, P.W.; Flores-Mir, C.; Gozal, D. Biomarkers associated with obstructive sleep apnea and morbidities: A scoping review. Sleep Med. 2015, 16, 347–357.
  53. Cortese, R.; Gileles-Hillel, A.; Khalyfa, A.; Almendros, I.; Akbarpour, M.; Khalyfa, A.A.; Qiao, Z.; Garcia, T.; Andrade, J.; Gozal, D. Aorta macrophage inflammatory and epigenetic changes in a murine model of obstructive sleep apnea: Potential role of CD36. Sci. Rep. 2017, 7, 43648.
  54. Gozal, D.; Khalyfa, A.; Qiao, Z.; Almendros, I.; Farré, R. Temporal trajectories of novel object recognition performance in mice exposed to intermittent hypoxia. Eur. Respir. J. 2017, 50, 1701456.
  55. Cao, Z.; Zhang, P.; He, Z.; Yang, J.; Liang, C.; Ren, Y.; Wu, Z. Obstructive sleep apnea combined dyslipidemia render additive effect on increasing atherosclerotic cardiovascular diseases prevalence. Lipids Health Dis. 2016, 15, 98.
  56. Lee, C.H.; Sethi, R.; Li, R.; Ho, H.H.; Hein, T.; Jim, M.H.; Loo, G.; Koo, C.Y.; Gao, X.F.; Chandra, S.; et al. Obstructive sleep apnea and cardiovascular events after percutaneous coronary intervention. Circulation 2016, 133, 2008–2017.
  57. Yaggi, H.K.; Mittleman, M.A.; Bravata, D.M.; Concato, J.; Ware, J.; Stoney, C.M.; Redline, S. Reducing cardiovascular risk through treatment of obstructive sleep apnea: Methodological approaches. Am. Heart J. 2016, 172, 135–143.
  58. Monneret, D.; Tamisier, R.; Ducros, V.; Faure, P.; Halimi, S.; Baguet, J.P.; Lévy, P.; Pépin, J.L.; Borel, A.L. Glucose tolerance and cardiovascular risk biomarkers in non-diabetic non-obese obstructive sleep apnea patients: Effects of long-term continuous positive airway pressure. Respir. Med. 2016, 112, 119–125.
  59. Bauters, F.; Rietzschel, E.R.; Hertegonne, K.B.; Chirinos, J.A. The link between obstructive sleep apnea and cardiovascular disease. Curr. Atheroscler. Rep. 2016, 18, 1.
  60. Kostopoulos, K.; Alhanatis, E.; Pampoukas, K.; Georgiopoulos, G.; Zourla, A.; Panoutsopoulos, A.; Kallianos, A.; Velentza, L.; Zarogoulidis, P.; Trakada, G. CPAP therapy induces favorable short-term changes in epicardial fat thickness and vascular and metabolic markers in apparently healthy subjects with obstructive sleep apnea-hypopnea syndrome (OSAHS). Sleep Breath. 2016, 20, 483–493.
  61. Schwarz, E.I.; Puhan, M.A.; Schlatzer, C.; Stradling, J.R.; Kohler, M. Effect of CPAP therapy on endothelial function in obstructive sleep apnoea: A systematic review and meta-analysis. Respirology 2015, 20, 889–895.
  62. De Araújo Freitas, I.G.; de Bruin, P.F.; Bittencourt, L.; de Bruin, V.M.; Tufik, S. What can blood biomarkers tell us about cardiovascular risk in obstructive sleep apnea? Sleep Breath. 2015, 19, 755–768.
  63. Gouveris, H.; Bahr, K.; Jahn, C.; Matthias, C.; Simon, P. The Apnea-Hypopnea Index Underestimates Systemic Inflammation in Women with Sleep-Disordered Breathing. J. Womens Health (Larchmt.) 2018, 27, 920–926.
  64. Churchill, L.; Rector, D.M.; Yasuda, K.; Fix, C.; Rojas, M.J.; Yasuda, T.; Krueger, J.M. Tumor necrosis factor alpha: Activity dependent expression and promotion of cortical column sleep in rats. Neuroscience 2008, 156, 71–80.
  65. Rockstrom, M.D.; Chen, L.; Taishi, P.; Nguyen, J.T.; Gibbons, C.M.; Veasey, S.C.; Krueger, J.M. Tumor necrosis factor alpha in sleep regulation. Sleep Med. Rev. 2018, 40, 69–78.
  66. Krueger, J.M.; Opp, M.R. Sleep and Microbes. Int. Rev. Neurobiol. 2016, 131, 207–225.
  67. Jewett, K.A.; Taishi, P.; Sengupta, P.; Roy, S.; Davis, C.J.; Krueger, J.M. Tumor necrosis factor enhances the sleep-like state and electrical stimulation induces a wake-like state in co-cultures of neurons and glia. Eur. J. Neurosci. 2015, 42, 2078–2090.
  68. Ramesh, V.; Thatte, H.S.; McCarley, R.W.; Basheer, R. Adenosine and sleep deprivation promote NF-kappaB nuclear translocation in cholinergic basal forebrain. J. Neurochem. 2007, 100, 1351–1363.
  69. Kaushal, N.; Ramesh, V.; Gozal, D. TNF-α and temporal changes in sleep architecture in mice exposed to sleep fragmentation. PLoS ONE 2012, 7, e45610.
  70. Ramesh, V.; Nair, D.; Zhang, S.X.; Hakim, F.; Kaushal, N.; Kayali, F.; Wang, Y.; Li, R.C.; Carreras, A.; Gozal, D. Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-α pathway. J. Neuroinflamm. 2012, 9, 91.
  71. He, K.; Kapur, V.K. Sleep-disordered breathing and excessive daytime sleepiness. Sleep Med. Clin. 2017, 12, 369–382.
  72. Gozal, D.; Kheirandish-Gozal, L. Obesity and excessive daytime sleepiness in prepubertal children with obstructive sleep apnea. Pediatrics 2009, 123, 13–18.
  73. Tauman, R.; O’Brien, L.M.; Holbrook, C.R.; Gozal, D. Sleep pressure score: A new index of sleep disruption in snoring children. Sleep 2004, 27, 274–278.
  74. Gozal, D.; Wang, M.; Pope, D.W., Jr. Objective sleepiness measures in pediatric obstructive sleep apnea. Pediatrics 2001, 108, 693–697.
  75. Strohl, K.P. Tumor necrosis factor and sleep apnea. Am. J. Respir. Crit. Care Med. 1996, 153, 893.
  76. Domínguez-Álvarez, M.; Gea, J.; Barreiro, E. Inflammatory Events and Oxidant Production in the Diaphragm, Gastrocnemius, and Blood of Rats Exposed to Chronic Intermittent Hypoxia: Therapeutic Strategies. J. Cell Physiol. 2017, 232, 1165–1175.
  77. Nácher, M.; Farré, R.; Montserrat, J.M.; Torres, M.; Navajas, D.; Bulbena, O.; Serrano-Mollar, A. Biological consequences of oxygen desaturation and respiratory effort in an acute animal model of obstructive sleep apnea (OSA). Sleep Med. 2009, 10, 892–897.
  78. Taylor, C.T.; Kent, B.D.; Crinion, S.J.; McNicholas, W.T.; Ryan, S. Human adipocytes are highly sensitive to intermittent hypoxia induced NF-kappaB activity and subsequent inflammatory gene expression. Biochem. Biophys. Re.s Commun. 2014, 447, 660–665.
  79. Da Rosa, D.P.; Forgiarini, L.F.; Baronio, D.; Feijó, C.A.; Martinez, D.; Marroni, N.P. Simulating sleep apnea by exposure to intermittent hypoxia induces inflammation in the lung and liver. Mediators Inflamm. 2012, 2012, 879419.
  80. Song, D.; Fang, G.; Mao, S.Z.; Ye, X.; Liu, G.; Gong, Y.; Liu, S.F. Chronic intermittent hypoxia induces atherosclerosis by NF-κB-dependent mechanisms. Biochim. Biophys. Acta 2012, 1822, 1650–1659.
  81. Dyugovskaya, L.; Polyakov, A.; Ginsberg, D.; Lavie, P.; Lavie, L. Molecular pathways of spontaneous and TNF--mediated neutrophil apoptosis under intermittent hypoxia. Am. J. Respir. Cell Mol. Biol. 2011, 45, 154–162.
  82. Ryan, S.; Taylor, C.T.; McNicholas, W.T. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am. J. Respir. Crit. Care Med. 2006, 174, 824–830.
  83. Poulain, L.; Richard, V.; Lévy, P.; Dematteis, M.; Arnaud, C. Toll-like receptor-4 mediated inflammation is involved in the cardiometabolic alterations induced by intermittent hypoxia. Mediators Inflamm. 2015, 2015, 620258.
  84. Lavie, L.; Polotsky, V. Cardiovascular aspects in obstructive sleep apnea syndrome—molecular issues, hypoxia and cytokine profiles. Respiration 2009, 78, 361–370.
  85. O’Halloran, K.D.; Lewis, P.; McDonald, F. Sex, stress and sleep apnoea: Decreased susceptibility to upper airway muscle dysfunction following intermittent hypoxia in females. Respir. Physiol. Neurobiol. 2017, 245, 76–82.
  86. O’Halloran, K.D. Chronic intermittent hypoxia creates the perfect storm with calamitous consequences for respiratory control. Respir. Physiol. Neurobiol. 2016, 226, 63–67.
  87. McDonald, F.B.; Williams, R.; Sheehan, D.; O’Halloran, K.D. Early life exposure to chronic intermittent hypoxia causes upper airway dilator muscle weakness, which persists into young adulthood. Exp. Physiol. 2015, 100, 947–966.
  88. Edge, D.; O’Halloran, K.D. Chronic Intermittent Hypoxia Blunts the Expression of Ventilatory Long Term Facilitation in Sleeping Rats. Adv. Exp. Med. Biol. 2015, 860, 335–342.
  89. Edge, D.; McDonald, F.B.; Jones, J.F.; Bradford, A.; O’Halloran, K.D. Effect of chronic intermittent hypoxia on the reflex recruitment of the genioglossus during airway obstruction in the anesthetized rat. Prog. Brain Res. 2014, 209, 147–168.
  90. Shortt, C.M.; Fredsted, A.; Chow, H.B.; Williams, R.; Skelly, J.R.; Edge, D.; Bradford, A.; O’Halloran, K.D. Reactive oxygen species mediated diaphragm fatigue in a rat model of chronic intermittent hypoxia. Exp. Physiol. 2014, 99, 688–700.
  91. Reid, M.B.; Lannergren, J.; Westerblad, H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: Involvement of muscle myofilaments. Am. J. Respir. Crit. Care Med. 2002, 166, 479–484.
  92. Wilcox, P.; Milliken, C.; Bressler, B. High-dose tumor necrosis factor alpha produces an impairment of hamster diaphragm contractility. Attenuation with a prostaglandin inhibitor. Am. J. Respir. Crit. Care Med. 1996, 153, 1611–1615.
  93. Li, X.; Moody, M.R.; Engel, D.; Walker, S.; Clubb, F.J., Jr.; Sivasubramanian, N.; Mann, D.L.; Reid, M.B. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000, 102, 1690–1696.
  94. Krueger, J.M. The role of cytokines in sleep regulation. Curr. Pharm. Des. 2008, 14, 3408–3416.
  95. Wolf, J.; Rose-John, S.; Garbers, C. Interleukin-6 and its receptors: A highly regulated and dynamic system. Cytokine 2014, 70, 11–20.
  96. Gozal, D.; Gileles-Hillel, A.; Cortese, R.; Li, Y.; Almendros, I.; Qiao, Z.; Khalyfa, A.A.; Andrade, J.; Khalyfa, A. Visceral white adipose tissue after chronic intermittent and sustained hypoxia in mice. Am. J. Respir. Cell Mol. Biol. 2017, 56, 477–487.
  97. Poroyko, V.A.; Carreras, A.; Khalyfa, A.; Khalyfa, A.A.; Leone, V.; Peris, E.; Almendros, I.; Gileles-Hillel, A.; Qiao, Z.; Hubert, N.; et al. Chronic sleep disruption alters gut microbiota, induces systemic and adipose tissue inflammation and insulin resistance in mice. Sci. Rep. 2016, 6, 35405.
  98. Gileles-Hillel, A.; Kheirandish-Gozal, L.; Gozal, D. Biological plausibility linking sleep apnoea and metabolic dysfunction. Nat. Rev. Endocrinol. 2016, 12, 290–298.
  99. Zhang, S.X.; Khalyfa, A.; Wang, Y.; Carreras, A.; Hakim, F.; Neel, B.A.; Brady, M.J.; Qiao, Z.; Hirotsu, C.; Gozal, D. Sleep fragmentation promotes NADPH oxidase 2-mediated adipose tissue inflammation leading to insulin resistance in mice. Int. J. Obes. (Lond.) 2014, 38, 619–624.
  100. Gharib, S.A.; Khalyfa, A.; Abdelkarim, A.; Bhushan, B.; Gozal, D. Integrative miRNA-mRNA profiling of adipose tissue unravels transcriptional circuits induced by sleep fragmentation. PLoS ONE 2012, 7, e37669.
  101. Gharib, S.A.; Khalyfa, A.; Abdelkarim, A.; Ramesh, V.; Buazza, M.; Kaushal, N.; Bhushan, B.; Gozal, D. Intermittent hypoxia activates temporally coordinated transcriptional programs in visceral adipose tissue. J. Mol. Med. (Berl.) 2012, 90, 435–445.
  102. Lee, M.Y.; Wang, Y.; Mak, J.C.; Ip, M.S. Intermittent hypoxia induces NF-κB-dependent endothelial activation via adipocyte-derived mediators. Am. J. Physiol. Cell Physiol. 2016, 310, C446–C455.
  103. Lee, W.Y.; Allison, M.A.; Kim, D.J.; Song, C.H.; Barrett-Connor, E. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am. J. Cardiol. 2007, 99, 99–102.
  104. Esteve, E.; Castro, A.; López-Bermejo, A.; Vendrell, J.; Ricart, W.; Fernández-Real, J.M. Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care 2007, 30, 939–945.
  105. Schaefer, E.; Wu, W.; Mark, C.; Yang, A.; DiGiacomo, E.; Carlton-Smith, C.; Salloum, S.; Brisac, C.; Lin, W.; Corey, K.E.; et al. Intermittent hypoxia is a proinflammatory stimulus resulting in IL-6 expression and M1 macrophage polarization. Hepatol. Commun. 2017, 1, 326–337.
  106. Li, Y.; Vgontzas, A.N.; Fernandez-Mendoza, J.; Kritikou, I.; Basta, M.; Pejovic, S.; Gaines, J.; Bixler, E.O. Objective, but not subjective, sleepiness is associated with inflammation in sleep apnea. Sleep 2017, 40.
  107. Baessler, A.; Nadeem, R.; Harvey, M.; Madbouly, E.; Younus, A.; Sajid, H.; Naseem, J.; Asif, A.; Bawaadam, H. Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers—A meta-analysis. J. Inflamm. (Lond.) 2013, 10, 13.
  108. Van Eyck, A.; Van Hoorenbeeck, K.; De Winter, B.Y.; Van Gaal, L.; De Backer, W.; Verhulst, S.L. Sleep-disordered breathing, systemic adipokine secretion, and metabolic dysregulation in overweight and obese children and adolescents. Sleep Med. 2017, 30, 52–56.
  109. Smith, D.F.; Hossain, M.M.; Hura, A.; Huang, G.; McConnell, K.; Ishman, S.L.; Amin, R.S. Inflammatory milieu and cardiovascular homeostasis in children with obstructive sleep apnea. Sleep 2017, 40.
  110. Gaines, J.; Vgontzas, A.N.; Fernandez-Mendoza, J.; Calhoun, S.L.; He, F.; Liao, D.; Sawyer, M.D.; Bixler, E.O. Inflammation mediates the association between visceral adiposity and obstructive sleep apnea in adolescents. Am. J. Physiol. Endocrinol. Metab. 2016, 311, E851–E858.
  111. Huang, Y.S.; Guilleminault, C.; Hwang, F.M.; Cheng, C.; Lin, C.H.; Li, H.Y.; Lee, L.A. Inflammatory cytokines in pediatric obstructive sleep apnea. Medicine (Baltimore) 2016, 95, e4944.
  112. Kaditis, A.G.; Gozal, D.; Khalyfa, A.; Kheirandish-Gozal, L.; Capdevila, O.S.; Gourgoulianis, K.; Alexopoulos, E.I.; Chaidas, K.; Bhattacharjee, R.; Kim, J.; et al. Variants in C-reactive protein and IL-6 genes and susceptibility to obstructive sleep apnea in children: A candidate-gene association study in European American and Southeast European populations. Sleep Med. 2014, 15, 228–235.
  113. Zhong, A.; Xiong, X.; Shi, M.; Xu, H. Roles of interleukin (IL)-6 gene polymorphisms, serum IL-6 levels, and treatment in obstructive sleep apnea: A meta-analysis. Sleep Breath. 2016, 20, 719–731.
  114. Kong, D.; Qin, Z.; Wang, W.; Kang, J. Effect of obstructive sleep apnea on carotid artery intima media thickness related to inflammation. Clin. Investig. Med. 2017, 40, E25–E33.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Academic Video Service
Feedback